An HI survey of the Centaurus and Sculptor Groups - Constraints on the space density of low mass galaxies

We present results of two 21-cm HI surveys performed with the Australia Telescope Compact Array in the nearby Centaurus A and Sculptor galaxy groups. These surveys are sensitive to compact HI clouds and galaxies with HI masses as low as 3E+06 Msun, and are therefore among the most sensitive extragalactic HI surveys to date. The surveys consist of sparsely spaced pointings that sample approximately 2% of the groups' area on the sky. We detected previously known group members, but we found no new HI clouds or galaxies down to the sensitivity limit of the surveys. If the HI mass function had a faint end slope of alpha = 1.5 below M_{HI} = 10^{7.5} Msun in these groups, we would have expected ~3 new objects. Cold dark matter theories of galaxy formation predict the existence of a large number low mass DM sub-halos that might appear as tiny satellites in galaxy groups. Our results support and extend similar conclusions derived from previous HI surveys that a HI rich population of these satellites does not exist.Comment: Accepted for publication in A&

Parsec-scale HI absorption structure in a low-redshift galaxy seen against a Compact Symmetric Object

We present global VLBI observations of the 21-cm transition of atomic hydrogen seen in absorption against the radio source J0855+5751. The foreground absorber (SDSS~J085519.05+575140.7) is a dwarf galaxy at $z$ = 0.026. As the background source is heavily resolved by VLBI, the data allow us to map the properties of the foreground HI gas with a spatial resolution of 2pc. The absorbing gas corresponds to a single coherent structure with an extent $>$35pc, but we also detect significant and coherent variations, including a change in the HI optical depth by a factor of five across a distance of $\leq$6pc. The large size of the structure provides support for the Heiles & Troland model of the ISM, as well as its applicability to external galaxies. The large variations in HI optical depth also suggest that caution should be applied when interpreting $T_S$ measurements from radio-detected DLAs. In addition, the distorted appearance of the background radio source is indicative of a strong jet-cloud interaction in its host galaxy. We have measured its redshift ($z$ = 0.54186) using optical spectroscopy on the William Herschel Telescope and this confirms that J0855+5751 is a FRII radio source with a physical extent of $<$1kpc and supports the previous identification of this source as a Compact Symmetric Object. These sources often show absorption associated with the host galaxy and we suggest that both HI and OH should be searched for in J0855+5751.Comment: 14 pages and 10 figures. Accepted for publication in MNRA

Evaluating uncertain CO2 abatement over the very long term

Climate change research with the economic methodology of cost–benefit analysis is challenging because of valuation and ethical issues associated with the long delays between CO2 emissions and much of their potential damages, typically of several centuries. The large uncertainties with which climate change impacts are known today and the possibly temporary nature of some envisaged CO2 abatement options exacerbate this challenge. For example, potential leakage of CO2 from geological reservoirs, after this greenhouse gas has been stored artificially underground for climate control reasons, requires an analysis in which the uncertain climatic consequences of leakage are valued over many centuries. We here present a discussion of some of the relevant questions in this context and provide calculations with the top–down energy-environment-economy model DEMETER. Given the long-term features of the climate change conundrum as well as of technologies that can contribute to its solution, we considered it necessary extending DEMETER to cover a period from today until the year 3000, a time span so far hardly investigated with integrated assessment models of climate change

Exploring the causes of adverse events in hospitals and potential prevention strategies

Objectives To examine the causes of adverse events (AEs) and potential prevention strategies to minimise the occurrence of AEs in hospitalised patients. Methods For the 744 AEs identified in the patient record review study in 21 Dutch hospitals, trained reviewers were asked to select all causal factors that contributed to the AE. The results were analysed together with data on preventability and consequences of AEs. In addition, the reviewers selected one or more prevention strategies for each preventable AE. The recommended prevention strategies were analysed together with four general causal categories: technical, human, organisational and patient-related factors. Results Human causes were predominantly involved in the causation of AEs (in 61% of the AEs), 61% of those being preventable and 13% leading to permanent disability. In 39% of the AEs, patient-related factors were involved, in 14% organisational factors and in 4% technical factors. Organisational causes contributed relatively often to preventable AEs (93%) and AEs resulting in permanent disability (20%). Recommended strategies to prevent AEs were quality assurance/peer review, evaluation of safety behaviour, training and procedures. For the AEs with human and patient-related causes, reviewers predominantly recommended quality assurance/peer review. AEs caused by organisational factors were considered preventable by improving procedures. Discussion Healthcare interventions directed at human causes are recommended because these play a large role in AE causation. In addition, it seems worthwhile to direct interventions on organisational causes because the AEs they cause are nearly always believed to be preventable. Organisational factors are thus relatively easy to tackle. Future research designs should allow researchers to interview healthcare providers that were involved in the event, as an additional source of information on contributing factors.

Naked antibodies and antibody-drug conjugates:targeted therapy for childhood acute lymphoblastic leukemia

The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival rates exceeding 90%. The present and future challenges are to cure the remainder of patients still dying from disease, and to reduce morbidity and mortality in those who can be cured with standard-of-care chemotherapy by replacing toxic chemotherapy elements while retaining cure rates. With the novel therapeutic options introduced in the last years, including immunotherapies and targeted antibodies, the treatment of ALL is undergoing major changes. For B-cell precursor ALL, blinatumomab, an anti-CD19 bispecific antibody, has established its role in the consolidation treatment for both high- and standard-risk first relapse of ALL, in the presence of bone marrow involvement, and may also have an impact on the outcome of high-risk subsets such as infant ALL and Philadelphia chromosome-positive ALL. Inotuzumab ozogamicin, an anti-CD22 drug conjugated antibody, has demonstrated high efficacy in inducing complete remission in relapsed ALL, even in the presence of high tumor burden, but randomized phase III trials are still ongoing. For T-ALL the role of CD38-directed treatment, such as daratumumab, is gaining interest, but randomized data are needed to assess its specific benefit. These antibodies are currently being tested in patients with newly diagnosed ALL and may lead to major changes in the present paradigm of treatment of pediatric ALL. Unlike the past, lessons may be learned from innovations in adult ALL, in which more drastic changes are piloted that may need to be translated to pediatrics.</p

Naked antibodies and antibody-drug conjugates:targeted therapy for childhood acute lymphoblastic leukemia

The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival rates exceeding 90%. The present and future challenges are to cure the remainder of patients still dying from disease, and to reduce morbidity and mortality in those who can be cured with standard-of-care chemotherapy by replacing toxic chemotherapy elements while retaining cure rates. With the novel therapeutic options introduced in the last years, including immunotherapies and targeted antibodies, the treatment of ALL is undergoing major changes. For B-cell precursor ALL, blinatumomab, an anti-CD19 bispecific antibody, has established its role in the consolidation treatment for both high- and standard-risk first relapse of ALL, in the presence of bone marrow involvement, and may also have an impact on the outcome of high-risk subsets such as infant ALL and Philadelphia chromosome-positive ALL. Inotuzumab ozogamicin, an anti-CD22 drug conjugated antibody, has demonstrated high efficacy in inducing complete remission in relapsed ALL, even in the presence of high tumor burden, but randomized phase III trials are still ongoing. For T-ALL the role of CD38-directed treatment, such as daratumumab, is gaining interest, but randomized data are needed to assess its specific benefit. These antibodies are currently being tested in patients with newly diagnosed ALL and may lead to major changes in the present paradigm of treatment of pediatric ALL. Unlike the past, lessons may be learned from innovations in adult ALL, in which more drastic changes are piloted that may need to be translated to pediatrics.</p

Orange-Red to Yellowish Brown Cordierite from Madagascar

Gem-quality cordierite is typically seen as blue material (iolite), showing strong pleochroism in yellow, light blue and dark violet-blue. However, in late 2014 one of the authors (FP) learned about a new occurrence of a much different cordierite, which typically ranged from dark orange-red to yellowish brown. The material is recovered by local miners from weathered residual deposits in southern Madagascar, probably in the Gogogogo area, north of Ampanihy in Tuléar Province. One of the authors (FP) obtained about 120 kg of rough material of mixed quality from the miners over a period of a few months, from which only a few kilograms were suitable for cutting cabochons and faceted stones

Comparing Galaxies and Lyman Alpha Absorbers at Low Redshift

A scenario is explored in which Lyman alpha absorbers at low redshift arise from lines of sight through extended galaxy disks, including those of dwarf and low surface brightness galaxies. A population of galaxies is simulated based upon observed distributions of galaxy properties, and the gas disks are modeled using pressure and gravity confinement. Some parameter values are ruled out by comparing simulation results with the observed galaxy luminosity function, and constraints may be made on the absorbing cross sections of galaxies. Simulation results indicate that it is difficult to match absorbers with particular galaxies observationally since absorption typically occurs at high impact parameters (>200 kpc) from luminous galaxies. Low impact parameter absorption is dominated by low luminosity dwarfs. A large fraction of absorption lines is found to originate from low surface brightness galaxies, so that the absorbing galaxy is likely to be misidentified. Low redshift Lyman alpha absorber counts can easily be explained by moderately extended galaxy disks when low surface brightness galaxies are included, and it is easily possible to find a scenario which is consistent with observed the galaxy luminosity function, with low redshift Lyman limit absorber counts, and with standard nucleosynthesis predictions of the baryon density, Omega_Baryon.Comment: 17 pages, 8 figures, accepted to the Astrophysical Journa